Loading...
XASX
HPC
Market cap2mUSD
Jun 11, Last price  
0.01AUD
Name

Hydration Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
P/E
0.93
P/S
0.77
EPS
0.01
Div Yield, %
Shrs. gr., 5y
36.27%
Rev. gr., 5y
1.58%
Revenues
3m
-68.08%
4,161,1822,962,8253,756,6955,918,5809,099,96810,041,1843,204,940
Net income
3m
P
-9,602,288-3,434,151-743,663-8,966,505-10,607,166-8,102,3782,667,533
CFO
-3m
L-47.30%
-5,395,365-2,781,297-3,862,323-8,078,049-9,751,840-5,729,705-3,019,549

Profile

The Hydration Pharmaceuticals Company Limited markets and sells a range of liquid, tablet, and powder healthy hydration products in Australia, the Unites States, and Canada. It sells its products under the Hydralyte brand name through retail stores and e-commerce channels. The company was founded in 2001 and is headquartered in San Diego, California.
IPO date
Dec 14, 2021
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
3,205
-68.08%
10,041
10.34%
9,100
53.75%
Cost of revenue
7,402
17,783
19,802
Unusual Expense (Income)
NOPBT
(4,197)
(7,742)
(10,702)
NOPBT Margin
Operating Taxes
(1)
274
Tax Rate
NOPAT
(4,197)
(7,742)
(10,975)
Net income
2,668
-132.92%
(8,102)
-23.61%
(10,607)
18.30%
Dividends
Dividend yield
Proceeds from repurchase of equity
(24)
2,716
BB yield
0.50%
-57.99%
Debt
Debt current
Long-term debt
3,893
3,712
Deferred revenue
Other long-term liabilities
21
23
22
Net debt
(3,217)
2,052
(976)
Cash flow
Cash from operating activities
(3,020)
(5,730)
(9,752)
CAPEX
Cash from investing activities
9,444
Cash from financing activities
(3,628)
2,716
4,076
FCF
(2,479)
(6,433)
(11,428)
Balance
Cash
3,217
1,840
4,688
Long term investments
Excess cash
3,056
1,338
4,233
Stockholders' equity
2,742
(358)
3,981
Invested Capital
21
3,916
3,734
ROIC
ROCE
EV
Common stock shares outstanding
266,753
195,129
162,680
Price
0.02
-25.00%
0.02
-73.33%
0.09
-70.00%
Market cap
4,802
2.53%
4,683
-68.01%
14,641
-35.39%
EV
1,585
6,736
13,665
EBITDA
(4,197)
(7,742)
(10,702)
EV/EBITDA
Interest
1,764
643
91
Interest/NOPBT